CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
61.67
+1.35 (2.24%)
At close: Sep 26, 2025, 4:00 PM EDT
61.36
-0.31 (-0.50%)
After-hours: Sep 26, 2025, 7:59 PM EDT
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 17 analysts that cover CRISPR Therapeutics AG stock have a consensus rating of "Buy" and an average price target of $72.59, which forecasts a 17.71% increase in the stock price over the next year. The lowest target is $32 and the highest is $120.
Price Target: $72.59 (+17.71%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Buy | 4 | 3 | 3 | 3 | 3 | 4 |
| Hold | 8 | 6 | 7 | 6 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 16 | 17 | 16 | 16 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +29.72% | Sep 23, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $70 | Buy | Initiates | $70 | +13.51% | Sep 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $65 → $80 | Strong Buy | Maintains | $65 → $80 | +29.72% | Aug 7, 2025 |
| Barclays | Barclays | Hold Maintains $42 → $56 | Hold | Maintains | $42 → $56 | -9.19% | Aug 6, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $82 | Strong Buy | Maintains | $82 | +32.97% | Aug 5, 2025 |
Financial Forecast
Revenue This Year
34.81M
from 37.31M
Decreased by -6.72%
Revenue Next Year
155.99M
from 34.81M
Increased by 348.18%
EPS This Year
-6.33
from -4.34
EPS Next Year
-4.39
from -6.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 134.7M | 1.5B | |||
| Avg | 34.8M | 156.0M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 260.9% | 4,287.3% | |||
| Avg | -6.7% | 348.2% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.37 | 2.89 | |||
| Avg | -6.33 | -4.39 | |||
| Low | -7.18 | -6.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.